Alterity Therapeutics (ASX:ATH) Scaled Net Operating Assets: N/A (As of Dec. 2025)

What is Alterity Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Alterity Therapeutics's operating assets for the quarter that ended in Dec. 2025 was A$7.72 Mil. Alterity Therapeutics's operating liabilities for the quarter that ended in Dec. 2025 was A$2.55 Mil. Alterity Therapeutics's Total Assets for the quarter that ended in Sep. 2025 was A$0.00 Mil. Therefore, Alterity Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was N/A.

Alterity Therapeutics Scaled Net Operating Assets Related Terms

Alterity Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Scaled Net Operating Assets Chart

Alterity Therapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.24

0.02

0.18

0.05

0.10

Alterity Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

ASX:ATH vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Alterity Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Scaled Net Operating Assets falls into.

Save Embed

34GF Score

Alterity Therapeutics Ltd ASX:ATH

Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Alterity Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Alterity Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2025 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2025 )
=	(Operating Assets (A: Jun. 2025 )	-	Operating Liabilities (A: Jun. 2025 ))	/	Total Assets (A: Jun. 2024 )
=	(5.367	-	3.467)	/	19.224
=	0.10

where

	Operating Assets		(A: Jun. 2025 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	46.026	-	40.659
=	5.367

	Operating Liabilities		(A: Jun. 2025 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	3.623	-	0.089	-	0.067
=	3.467

Alterity Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2025 )
=	(Operating Assets (Q: Dec. 2025 )	-	Operating Liabilities (Q: Dec. 2025 ))	/	Total Assets (Q: Sep. 2025 )
=	(7.718	-	2.553)	/	0
=	N/A

where

	Operating Assets		(Q: Dec. 2025 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	56.919	-	49.201
=	7.718

	Operating Liabilities		(Q: Dec. 2025 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.651	-	0.065	-	0.033
=	2.553

Alterity Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:PAR ASX:ALA ASX:DXB ASX:ILA ASX:PTX ASX:IMM ASX:NYR ASX:ATX ASX:LTP ASX:CYP VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ATHE:USA PBN:Germany

Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000

Website https://www.alteritytherapeutics.com

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

34GF Score

Get the complete analysis for ASX:ATH

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56

Price

View ASX:ATH Analysis

See Scaled Net Operating Assets data for all stocks →